There is at present no uniformity in the technique of endoscopic sclerotherapy and various workers have used different equipment modifications and treatment schedules. In the present study we describe our experience using a standard fibre-optic
Endoscopic sclerotherapy for oesophageal varices is now an accepted mode of treatment for the management of acute variceal bleeding as well as for the prevention of recurrent bleeding. [1] [2] [3] [4] [5] [6] [7] This procedure is carried out with the help of sclerosants such as ethanolamine oleate,3 4 8 sodium morrhuate,7 9 sodium tetradecyl sulphatel' and polydocanol.1" Although these solutions are very effective, they are expensive and are not easily available in developing countries such as India. In search for an effective and freely available agent we have assessed the efficacy and safety of absolute alcohol as a sclerosant in the treatment of oesophageal varices.
There is at present no uniformity in the technique of endoscopic sclerotherapy and various workers have used different equipment modifications and treatment schedules. In the present study we describe our experience using a standard fibre-optic endoscope without any modifications, an easy to design injector, use of absolute alcohol as a sclerosant, and a weekly schedule of sclerotherapy. tion.14 The assessment was made by an independent endoscopist and recorded. In addition, a careful search was made for gastric varices. Endoscopic sclerotherapy was started from the lowest point in the variceal column near the cardiac end of the oesophagus and the injections were made circumferentially. The endoscope was withdrawn by 1-2 cm and another set of injections was made. The injector needle was first introduced into a varix and then withdrawn by a millimetre or two to ensure that the injector tip had not pierced the oesophageal wall. About 0*52 ml of absolute alcohol was injected at each site with a total of 3-18 ml per endoscopic sclerotherapy session. The quantity decreased as the varices became obliterated. After completion of a course of injections, the endoscope was pushed into the stomach in order to decompress it by aspirating the air and secretions and then withdrawn after ensuring complete haemostasis. Sengstaken tube was not used and the patients were allowed food after about an hour. Fifteen to 30 ml liquid antacid was 121 administered every four hours.
In patients with active variceal bleeding, the endoscopic field was first cleared by repeated suction and flushing and the bottom end of the variceal column at the gastroesophageal junction was identified and injected. A search was then made for any bleeding point on the varix and if visible injections were made around it until complete haemostasis was achieved.
Endoscopic sclerotherapy was repeated at regular weekly intervals. Repeat injections were given at a distance of about 25cm from previous injection sites, avoiding ulcerated areas. Endoscopic sclerotherapy was, however, deferred when ulcers were present diffusely over the varices.
Results
One hundred and fifty nine sclerotherapy sessions were given to 43 patients.
CONTROL OF ACUTE HAEMORRHAGE
All seven patients with acute bleeding uncontrolled by balloon tamponade and four patients with a rebleed after the first course of elective sclerotherapy were successfully controlled by a single course of endoscopic sclerotherapy, giving an over all success rate of 100%. In acute bleeders, the indigenously designed injector was found to be especially useful as the injections could be made rapidly. None of these patients rebled. No patient has required emergency surgery since the introduction of endoscopic sclerotherapy at our centre.
VARICEAL REDUCTION AND ERADICATION
Because the success of endoscopic sclerotherapy depends on the adequacy of variceal sclerosis and the results are likely to improve with repeated courses we arbitrarily separated our patients into two groups. Group I received four or more courses of endoscopic sclerotherapy and group II received less than four courses (Table 1) . In group I, reduction in variceal size by two or more grades was achieved in all the patients while total eradication of varices was seen in 80% patients (Table 2) . By contrast, in group II, reduction in variceal size was seen in only one (2.4%) patient who completed three courses of endoscopic sclerotherapy.
To check for recurrences, patients with complete obliteration of varices were re-endoscoped by an independent observer on at least two occasions spaced one month apart. None of the patients have shown appearance of fresh varices either in the oesophagus or in the stomach during a mean follow up of 18-47±8.50 weeks with a range of six to 38 weeks ( Table 2) . Oliguria developed within six to eight hours of sclerotherapy in four patients. It lasted from 12-48 hours and normal urine output returned in all the patients after a short course of parenteral frusemide. Blood urea values remained within normal limits. All the four patients had moderate ascites, three were in Child's C and one in Child's B category. A sudden increase in ascites was also noted in one of the patients during the period of oliguria.
Discussion
Absolute alcohol was found to be an effective and safe sclerosant. Using this agent, acute variceal bleeding was successfully controlled in 11 patients; seven with fresh bleed and four with a rebleed while on endoscopic sclerotherapy regimen. Reduction in variceal size of two or more grades was achieved in all 20 patients who had received four or more endoscopic sclerotherapy courses. Total eradication of varices was achieved in 16 (80%) of these patients. These results are comparable with other sclerosants.1 2 7 8 11 Besides efficacy, alcohol has a number of advantages; it is economical -a complete course of endoscopic sclerotherapy costs less than two rupees (approximately 13 pence), there is no problem of sterilisation of the injector or the sclerosant because alcohol is itself a strong disinfectant, and above all it is freely available; an important consideration in the third world countries.
The injector devised by us is simple to prepare and was found to be superior to the more expensive commercial one (Olympus NM-1K Injector). It is easier to introduce through the biopsy channel, its 21 gauge needle allows more rapid introduction of the sclerosant and the injections are made under direct vision because the sclerosant can be seen through the transparent Teflon tube.
There is no accepted standard technique of endoscopic sclerotherapy and various workers differ in the type of endoscope and sclerosant used, use of balloon tamponade after endoscopic sclerotherapy, urgency of the procedure, site of injection (intravariceal or paravariceal) and the frequency of reinjections. The different modifications of the endoscope used include the use of a rigid Negus oeosphagoscope,' 2 7 a flexible sheath with a window cut at its distal end used on a side-viewing endoscope,3 Olympus EFB2 or EFB3 endoscope with a side balloon made of Teflon'5 or use of a 'Lowa' balloon attached to the endoscope. 9 In the present study, we successfully used Olympus G1F-D3 and G1F-Q endoscopes without any of the above modifications.
There is a controversy regarding the use of balloon compression after endoscopic sclerotherapy to retard blood flow and to prolong the contact time of the sclerosant with the variceal wall.' 16 There is no clear agreement with regard to the ideal interval between endoscopic sclerotherapy courses, and most workers empirically follow a protocol of three to six weeks. It is argued that intervals shorter than these are associated with the problems of oesophageal ulcers, stricture formation, and poor patient compliance.3 As the risk of rebleeding or death rapidly dirninishes over the first few days after a bleed,'8 and the chances of rebleeding are as high as 70% in partially ablated varices,11 we adopted a policy of weekly injections.
Besides reducing the danger of rebleeding and attaining early eradication of varices, we found the weekly schedule acceptable to most patients; our drop out rate was low (5%) and the problem of hospital stay and transport was minimised.
There were no fatal complications in our series and all six mortalities were because of progressive hepatic failure and encephalopathy. The incidence of oesophageal ulcers was higher in our study compared with the previous reports.3 7 8 This is probably due to the fact that we were recording their presence at the end of one week as against other studies where repeat endoscopy was performed three to six weeks after endoscopic sclerotherapy. The oesophageal ulcers did not, however, interfere with subsequent injections in our patients; we simply avoided the ulcerated areas and injected at sites 1-2 cm away. It is interesting to note that the frequency of retrosternal pain was unrelated to the presence of oesophageal ulcers. Moreover, stricture formation did not necessarily follow oesophageal ulcerations. Only 7% patients developed strictures compared with 61% patients with oesophageal ulcers. Thus, the incidence of oesophageal stricture formation using absolute alcohol on weekly basis was no higher than conventional sclerotherapy schedules.3 78 11 The strictures were easily dilated with metal (Eder-Puestow) dilators and all except one patient recovered completely.
Transient oliguria was seen in four patients. This complication has not been reported with other sclerosants and we are unsure about the mechanism of this defect as there was no rise in the serum urea levels and none of the patients developed hepatorenal syndrome.
In conclusion, we should like to argue in favour of aggressive sclerotherapy. We feel that endoscopic sclerotherapy should form the first line treatment in acute variceal bleeding. It also appears to be highly effective in preventing rebleeding. A weekly schedule of sclerotherapy was found safe and effective. We recommend absolute alcohol as a sclerosant as it is very effective, economical, safe, and freely available. These are preliminary observations, however, and much more experience with a larger number of patients is required to assess the overall long term benefits of endoscopic sclerotherapy.
